DailyIQ
Last updatedUpdating…

HIMS·Hims & Hers Health, Inc.

$27.69
-2.02 (-6.80%)
After Hours
High
$29.86
Open
$29.26
Market Cap
6.93B
52W High
$65.30
Low
$27.56
P. Close
$27.69
P/E
54.00
52W Low
$13.74
Fwd P/E
40.30
DailyIQ Est.
$31.57
Inst. Ownership
39.6%
Short Interest
23.59%
Days to Cover
5.3
Technical Score (1D)
4
BEARISH
News Sentiment
56
BULLISH
On Oct 12, SeekingAlpha rated Hims & Hers Health (HIMS) as a buy, citing a fair value estimate of $41 per share against the then‑current price of $29.81. The rating reflected confidence in the company’s growth prospects and valuation upside. The recommendation suggested potential upside for investors if the stock approached the target price. No other developments were reported for the company on that date.
LOW TARGET
$23 -17.0%
2 analysts
MEAN TARGET
$31 +12.4%
16 analysts
HIGH TARGET
$42 +51.5%
6 analysts
PRICE RANGE
$23.00 - $42.00
SB / B / H / S / SS
2/7/13/1/1
DAILYIQ EST.
$31.57 (+13.9%)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NYQ
Country
United States
Website
Symbol
HIMS
Description
Hims & Hers Health, Inc. operates a telehealth platform facilitating direct-to-consumer access to healthcare services and products. The company's core offering centers on providing prescription medications and ongoing care, complemented by a selection of over-the-counter health and wellness products. These products span diverse categories, including general wellness, sexual health, skincare, and hair care, all available for purchase through its online platform and mobile application. Hims & Hers distinguishes itself by offering curated product selections and medical consultations, along with post-consultation support. Furthermore, the company offers Labs, a service providing personalized health insights and action plans.
Bought (1Y)
48,400 shares
$1.2M
Sold (1Y)
1,001,079 shares
$29.9M
Okupe OluyemiChief Financial Officer
Sell2,000 shares2026-10-01
Boughton SoleilChief Legal Officer
Sell3,461 shares2026-09-30
Okupe OluyemiChief Financial Officer
Option Exercise14,000 shares2026-09-22
Okupe OluyemiChief Financial Officer
Sell29,277 shares2026-09-22
Okupe OluyemiChief Financial Officer
Option Exercise14,000 shares2026-09-22
72/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
73.8%
Net Margin
5.5%
Revenue CAGR
74.7%
Current Ratio
1.90x
Return on Equity
23.7%
Earnings Summary
Hims & Hers Health, Inc. operates a telehealth platform that delivers prescription medications, ongoing care, and a range of over‑the‑counter wellness products through its online portal and mobile app, positioning it within the specialty drug manufacturing and direct‑to‑consumer healthcare sector. The company’s model blends medical consultations with curated product offerings, supported by a Labs service that provides personalized health insights. In recent quarters, Hims & Hers reported revenue growth that has fluctuated, with Q1 2025 revenue rising to $586.01 million from $481.14 million in Q4 2024, a 21.4% increase, while Q2 2025 revenue fell to $544.83 million, a 7.8% decline from Q1 2025; Q3 2025 revenue rose again to $598.98 million, a 9.5% increase over Q2 2025. EPS performance has been volatile: the company beat estimates in Q1 2025 (EPS $0.20 vs $0.121) and Q2 2025 (EPS $0.17 vs $0.165), but missed in Q3 2025 (EPS $0.06 vs $0.102) and Q4 2025 (EPS $0.07 vs $0.249). Historically, the firm has shown a YoY revenue CAGR of roughly 22% over the past few years, with several quarters of revenue growth despite EPS misses, indicating a focus on scaling subscriber base over profitability. Recent news highlights the appointment of new chief medical officers in the UK, EMEA, and Australia to support international expansion, and the launch of an AI‑native weight‑loss care platform, both aimed at driving subscriber acquisition and cross‑sell opportunities.

EPS

EstBeatMiss
$-0.24$-0.10$0.03$0.17$0.31Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.15 - -
Q2'26$0.11$-0.10-187.1%
Q1'26$0.13$-0.18-235.8%
Q4'25$0.25$0.07-71.9%
Q3'25$0.10$0.06-41.0%
Q2'25$0.16$0.17+3.2%

Revenue

EstBeatMiss
$493M$606M$719M$832M$945MQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$893M - -
Q2'26$714M$753M+5.5%
Q1'26$629M$608M-3.4%
Q4'25$653M$618M-5.3%
Q3'25 - $599M -
Q2'25 - $545M -

Market Data

HIMS Stock Snapshot

BEARISH4/100
$27.65−$0.04 (0.1%)
Market cap
6.93B
P/E ratio
54.0
Day range
$27.56 – $29.86
News sentiment
56/100 · Neutral
Analyst target
$31.15 (+12.7%)
Consensus
Hold · 24 analysts
52-week range+101.2% off low · -57.7% from high
$13.74$65.30
Price $27.65 DailyIQ Est. $31.57

Price action on HIMS is defensive - rallies are being sold rather than extended. At this size, a single catalyst moves the stock further than it would a larger peer.

Behaviour On Record

What HIMS's own history says about today's numbers

Realized volatility (21d)
60.4% 39th pct
Below its peak
-59.6%
vs 200-day average
+1.5%
Up days (1y)
45%

Hims & Hers Health, Inc. is currently running 60.4% annualised volatility over the last 21 sessions. Measured against HIMS's own 7 years of daily returns rather than a market-wide average, that is the 39th percentile — on the quiet side for this stock, against a typical reading of 68.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

HIMS is trading -59.6% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -52.7%, and the deepest was -77.1% in 2021. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +1.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 43rd percentile — close to the gap it normally carries. Over the past year HIMS closed higher on 45% of sessions, and it is currently 3 sessions into a falling streak.

On October specifically: over 8 years of records, HIMS finished the month higher 1 of 8 times, with a median return of -6.2% and an average of -6.0%. Its strongest month historically has been November at +16.0% on average, its weakest August at -11.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: HIMS has opened more than 2% away from the prior close in 269 of 1,718 sessions (15.7% of the time), with the largest gaps running +14.4% and -8.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, HIMS moved an average of 4.3% in the session after earnings, closing higher 2 of those 3 times, with a median move of +2.9% and a largest of +8.5%.

All figures computed from 1,719 daily closes between 2019-09-13 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against HIMS's own 7-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of HIMS's sector?

Hims & Hers Health, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for HIMS?

CallsPuts

For Hims & Hers Health, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.66), with at-the-money implied volatility around 70.5%. The options market is pricing roughly a ±5.1% move by that expiry — a range of about $28.17–$31.19.

Put/call ratio (2026-10-16)
0.66
ATM implied volatility
70.5%
Total open interest
113,281
Expected move by 2026-10-16
±5.1% ($28.17–$31.19)

Analyst Rating Changes

Are analysts turning bullish or bearish on HIMS?

Truist Securities most recently reiterated its rating on Hims & Hers Health, Inc. to Hold on Aug 24, 2026 with a price target of $32 (from $27). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Truist Securities — Hold
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 24, 2026Truist SecuritiesMaintainedHold$27 → $32
Aug 21, 2026BarclaysMaintainedOverweight$39 → $35
Aug 11, 2026CitigroupMaintainedNeutral$35 → $33
Aug 11, 2026Deutsche BankMaintainedHold$25 → $26
Aug 11, 2026B of A SecuritiesMaintainedNeutral$30 → $32
Aug 11, 2026TD CowenMaintainedHold$25 → $30
Aug 11, 2026Morgan StanleyMaintainedEqual-Weight$21 → $28
Aug 11, 2026NeedhamMaintainedBuy$35 → $42
Jul 24, 2026Truist SecuritiesMaintainedHold$23 → $27
Jul 23, 2026CitigroupMaintainedNeutral$28 → $35
Jul 9, 2026B of A SecuritiesMaintainedNeutral$36 → $37
Jul 1, 2026Canaccord GenuityMaintainedBuy$32 → $40

Peers & ETF holders

HIMS peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

56/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
A recent analysis from SeekingAlpha rated Hims & Hers Health (HIMS) as a buy, citing a fair value estimate of $41 per share against the then-current price of $29.81. The rating reflects confidence in the company’s growth prospects and valuation upside. The recommendation suggests potential upside for investors if the stock approaches the target price.
What did this article say?
Hims & Hers Health announced the launch of a dedicated women's health platform in Australia, marking its first entry into the country’s telehealth market. The new service will offer virtual consultations for menstrual health, pregnancy, and menopause care, leveraging the company’s existing digital infrastructure. By entering Australia, HIMS aims to tap a growing demand for convenient, privacy‑focused health services and broaden its international footprint.
What did this article say?
Hims & Hers, Inc. scheduled to release its third‑quarter 2026 financial results on November 9, 2026. The announcement was made on October 12 via a Business Wire press release. The company’s disclosure confirms the planned reporting date but does not provide any financial guidance or performance details. Investors and analysts will await the earnings call for insights into revenue, profitability, and strategic updates.
What did this article say?
HIMS announced the launch of its Hers brand in Australia, marking its first entry into the Australian market. The company positioned the launch as a comprehensive approach to women's health, offering a range of products tailored to the local consumer base. The move is expected to broaden HIMS’s geographic reach and diversify its revenue streams. The announcement was made through a Business Wire release on October 12, 2024.
What did this article say?
Hims & Hers Health (HIMS) closed at $30.92 on October 9, rising 10.19% after a prior decline. The move was driven by a trading volume of 15.92 million shares, roughly 1.3 times the three‑month average, rather than any company‑specific news. Analysts noted that the price remains just below the street’s mean target of about $31, and the company’s 2030 revenue goal of $6.5 billion is higher than consensus estimates. The lack of a clear catalyst suggests the rally may be temporary, reflecting short‑term demand rather than a fundamental shift.
What did this article say?
On October 8, Hims & Hers Health, Inc. (HIMS) closed 5.01% lower at $28.06, underperforming the S&P 500’s modest decline. The drop came amid broader market volatility, with the Nasdaq falling 1.25% and the Dow gaining 0.1%. Investors noted that HIMS had a 5.88% monthly gain, outperforming the medical sector’s 3.97% loss. Analysts highlighted an upcoming earnings release that is expected to report $0.07 per share, a 16.67% year‑over‑year increase, and a 49.15% revenue rise to $893.37 million. The market reaction suggests short‑term concern despite the positive earnings outlook.
What did this article say?
Hims & Hers Health, Inc. (NYSE: HIMS) announced the appointment of Jon Franklin, a CPA with two decades of technical accounting experience, as its new Chief Accounting Officer. Franklin will report to CFO Yemi Okupe and oversee the company’s accounting organization as HIMS expands into new specialties and global markets. The move is intended to support the firm’s growth initiatives while building robust accounting infrastructure.
What did this article say?
Hims & Hers Health (HIMS) announced the appointment of Dr. Kultar Garcha as Chief Medical Officer for the UK and EMEA and Dr. Matt Vickers as Chief Medical Officer for Australia. The hires aim to strengthen clinical oversight and regulatory compliance in key growth markets. By adding region‑specific medical leadership, HIMS signals a commitment to scaling personalized digital health services worldwide. The move is expected to enhance investor confidence in the company’s international expansion strategy.
What did this article say?
Hims & Hers Health, Inc. (HIMS) has become a highly searched stock on Zacks.com, reflecting growing investor interest. Over the past month, HIMS shares rose 4.7%, outperforming both the S&P 500 composite and its industry peers. Zacks analysts emphasize that earnings estimate revisions are the primary driver behind the stock’s recent upward trajectory. The company’s strong performance in the medical information systems sector has bolstered confidence in its future earnings potential. This positive trend suggests that HIMS may continue to attract buying interest in the near term.

Technical Analysis

Real-time indicators across multiple timeframes

4
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $3.11B combined position · 15 adding, 9 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy28,703,51412.36%$995.15M2026-08-07
Vanguard Group Inc▲ Buy20,925,6669.01%$679.46M2026-01-29
Morgan Stanley▼ Sell7,152,4983.08%$247.98M2026-08-13
Geode Capital Management, LLC▲ Buy5,681,8322.45%$197.02M2026-08-12
Goldman Sachs Group Inc▲ Buy5,173,8652.23%$179.38M2026-08-14
JPMorgan Chase & Co▼ Sell4,766,7812.05%$159.48M2026-08-12
FMR LLC (Fidelity)▲ Buy4,323,2921.86%$149.89M2026-08-13
Marshall Wace, LLP▲ Buy4,217,7671.82%$146.23M2026-08-13
Northern Trust Corp▲ Buy2,594,2771.12%$89.94M2026-08-13
Bank of America Corp▼ Sell2,312,2721.00%$80.17M2026-08-14
Citadel Advisors LLC▲ Buy846,9360.36%$29.36M2026-09-02
Baillie Gifford & Co▲ New750,4910.32%$26.02M2026-08-06
Squarepoint Ops LLC▲ Buy617,3080.27%$21.40M2026-08-14
Wells Fargo & Company▼ Sell559,3890.24%$19.39M2026-08-14
Invesco Ltd.▲ Buy544,4840.23%$18.88M2026-08-14
Wellington Management Group LLP▼ Sell313,4630.13%$10.87M2026-08-14
AllianceBernstein L.P.▼ Sell438,8630.19%$9.11M2026-08-14
Citigroup Inc▼ Sell222,3010.10%$7.71M2026-08-03
Balyasny Asset Management L.P.▲ Buy218,9580.09%$7.59M2026-08-14
Sculptor Capital LP▲ Buy216,9000.09%$7.52M2026-08-14
AQR Capital Management LLC▲ Buy210,0840.09%$7.07M2026-08-14
Neuberger Berman Group LLC▲ Buy188,7480.08%$6.54M2026-08-13
D. E. Shaw & Co., Inc.▼ Sell171,5300.07%$5.95M2026-08-14
Davidson Kempner Capital Management LP• Hold160,0120.07%$5.55M2026-08-14
Winton Group Ltd▼ Sell159,5080.07%$5.53M2026-08-07
Q2 2026 flow:15.43M sh bought ($534.85M)5.95M sh sold ($204.69M)net +9.49M sh (+$330.16M)
Congressional Trading Activity
1 disclosed trades · ~$8.0K est. traded value · 1 buys, 0 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-08-042025-09-12